Cellyan Biotechnology (HKPD) Non-Current Debt (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Non-Current Debt of $1.5 million for Q1 2025, up 34.35% year-over-year from $1.1 million in Q1 2024, and up 49.54% quarter-over-quarter from $1.0 million in Q3 2024.
Cellyan Biotechnology (HKPD) Non-Current Debt (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Non-Current Debt data on file, last reported at $1.5 million in Q1 2025.
- Non-Current Debt for Q1 2025 came in at $1.5 million, up 34.35% year-over-year; the trailing twelve-month figure through Mar 2025 was $1.5 million (up 34.35% YoY), and the FY2025 annual result was $1.5 million, up 34.35% from the prior year.
- Non-Current Debt advanced to $1.5 million in Q1 2025 per HKPD's latest filing, from $1.0 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $1.5 million in Q1 2025 and troughed at $1.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 5.26 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 12.18 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 8.25 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 2.33 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 1.52 Bn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 17.60 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | - |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 1.34 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |